DLL3-SAVVYZ-IL18 CAR T cell

Phase 1

DLL3-SAVVYZ-IL18 CAR T cell is one of 11 therapeutic programs targeting Neuroendocrine Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neuroendocrine CancerRecruiting

Neuroendocrine CancerPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Neuroendocrine Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 2

1 2

Camptosar

Pfizer

Phase 2

1 3

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 5

Berzosertib

Merck & Co.

Phase 2

1 6

Keytruda

Merck & Co.

Phase 1

1 7

AK112

SSummit Therapeutics

Phase 2

1 8

Vepesid

AAvyxa

Phase 1

1 9

Paraplatin

AAvyxa

Phase 1

1 10

Taxotere

AAvyxa

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Neuroendocrine Cancer

NCT07783477

Clinical

Trials by Indication[1]

Neuroendocrine Cancer1 trial

A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07783477·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DLL3-SAVVYZ-IL18 CAR T cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for DLL3-SAVVYZ-IL18 CAR T cell. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

DLL3-SAVVYZ-IL18 CAR T cell

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Neuroendocrine Cancer1 trial

References

Drug Info

Quick Facts

Related News